Showing results (11-20 of 13) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Medical Economics|December 6, 2023
An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United StatesOlalekan O Oluwole, Anik R Patel, Sachin Vadgama, et al.Transplantation and Cellular Therapy|August 15, 2022
The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 TrialMiguel-Angel Perales, John Kuruvilla, Julia Thornton Snider, et al.Transplantation and Cellular Therapy|September 10, 2025
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell LymphomaMiguel-Angel Perales, Olalekan O Oluwole, Anik R Patel, et al.Pageof 2